No Data
No Data
Candel Therapeutics CEO Discusses Promising Phase 2 Pancreatic Cancer Trial Results - ICYMI | NASDAQ:CADL
Institutional Investors in Candel Therapeutics, Inc. (NASDAQ:CADL) See US$153m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
CCORF Maintains Candel Therapeutics(CADL.US) With Buy Rating, Raises Target Price to $25
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target
Candel Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Day One Biopharmaceuticals (DAWN)
Unlock the Full List